Spinal cord ischemia

Summary

Spinal cord ischemia (MONDO:0020688) is a disease and 4 clinical trials. A subtype of stroke disorder — broader associated-gene and molecular evidence is on the parent page (see Disease family below).

At a glance

• Clinical trials: 4

Clinical features

No curated clinical features (Orphanet) for this disease.

Identifiers

Disease identifiers

Field	Value
Canonical name	spinal cord ischemia
Mondo ID	MONDO:0020688
EFO	EFO:1001426
MeSH	D020760
UMLS	C0752130
MedGen	155706
Is cancer (heuristic)	no

Also known as: cord ischemia, spinal · cord Ischemias, spinal · experimental spinal cord ischemia · ischaemic myelopathies · ischaemic myelopathy · ischemia, spinal cord · ischemias, spinal cord · ischemic myelopathies · ischemic myelopathy · myelopathies, ischaemic · myelopathies, ischemic · myelopathy, ischaemic · myelopathy, ischemic · spinal cord ischemia, experimental · spinal cord Ischemias

Disease family

This is a subtype of stroke disorder. Genetic, therapeutic, and trial evidence is largely curated at the broader-term level — see the parent page for the associated-gene cohort and molecular evidence.

Classification path: disease › human disease › disease by body system or component › nervous system disorder › central nervous system disorder › brain disorder › cerebrovascular disorder › stroke disorder › spinal cord ischemia

Related subtypes (3): large artery stroke, ischemic stroke, hemorrhagic stroke

Subtypes (1): anterior spinal artery stroke

Genetics & variants

GWAS landscape

No GWAS associations recorded — common-variant (GWAS) studies don’t cover this disease (typical for Mendelian / rare diseases). See the curated gene cohort and Mendelian overlap below.

Variant details and genetic-evidence tiers

No tiered GWAS variants or ClinVar records for this disease.

Genes & proteins

No associated-gene cohort resolved for this disease. Atlas builds the molecular and therapeutic sections — associated genes, protein families, druggability, pathways, interactions, and drug associations — by aggregating over a disease’s associated genes (resolved via GWAS / GenCC / ClinVar / CIViC), and none resolved here. This is expected for antibody-mediated, autoimmune, or otherwise non-gene-defined conditions; the curated evidence for this disease is its clinical features, GWAS susceptibility, and clinical trials (above).

Function

No pathway enrichment — requires an associated-gene cohort.

Therapeutics

No druggable-target or therapeutic data for this disease’s cohort.

Clinical trials & evidence

Clinical trials

Clinical trials: 4.

Phase distribution (across all retrieved trials)

Phase	Trials
Not specified	4

Top trials by phase / activity

NCT	Phase	Status	Title
NCT03225625	Not specified	ENROLLING_BY_INVITATION	Stem Cell Spinal Cord Injury Exoskeleton and Virtual Reality Treatment Study
NCT03074487	Not specified	COMPLETED	Evaluating Monitoring Techniques for Postoperative Spinal Cord Ischemia
NCT04941157	Not specified	COMPLETED	Prophylactic vs Therapeutic Cerebrospinal Fluid Drain Placement During Endovascular Thoracoabdominal Aortic Aneurysm Repair
NCT06373393	Not specified	UNKNOWN	SPIRIT: Study of the Patency of Spinal aRteries After the STABILISE Technique